MAP2K7 and metastatic melanoma: Metastatic pattern and pretreatment LDH level have also been shown to be independent prognostic factors in other retrospective studies analyzing survival data in BRAF V600 mutant metastatic melanoma patients treated with first-line immune checkpoint inhibitors or BRAF + MEK inhibitors [53,54].